Preventing disease progression in Eisenmenger syndrome

References

• Van der linde D, Konings EEM, Slager MA, et al. Birth prevalence of congenital heart disease worldwide. J Am Coll Cardiol. 2011;58(21):2241–2247.
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014;35(11):691–700.
   PubMed Web of Science ®Google Scholar
• Engelfriet PM, Duffels MGJ, Moller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93(6):682–687.
   PubMed Web of Science ®Google Scholar
• National Pulmonary Hypertension Audit - 2012 [Internet]. NHS Digital. [ cited 2020 Jul 9]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/national-pulmonary-hypertension-audit/national-pulmonary-hypertension-audit-2012
   Google Scholar
• Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958;18(4):533–547.
   PubMed Web of Science ®Google Scholar
• Wood P. Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 1958;2(5099):755–762.
   PubMedGoogle Scholar
• Vongpatanasin W. The Eisenmenger syndrome in adults. Ann Intern Med. 1998;128(9):745.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.
   PubMed Web of Science ®Google Scholar
• Hjortshøj CS, Jensen AS, Sørensen K, et al. Epidemiological changes in Eisenmenger syndrome in the Nordic region in 1977–2012. Heart. 2017;103(17):1353–1358.
   PubMed Web of Science ®Google Scholar
• Kempny A, Dimopoulos K, Gatzoulis MA. Declining incidence and prevalence of Eisenmenger syndrome in the developed world: a triumph of modern medicine. Heart. 2017;103(17):1313–1314.
   PubMed Web of Science ®Google Scholar
• Kempny A, Dimopoulos K, Uebing A, et al. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life–single centre experience and review of published data. Eur Heart J. 2012;33(11):1386–1396.
   PubMed Web of Science ®Google Scholar
• Favoccia C, Kempny A, Yorke J, et al. EmPHasis-10 score for the assessment of quality of life in various types of pulmonary hypertension and its relation to outcome. Eur J Prev Cardiol. 2019;26(12):1338–1340.
   PubMed Web of Science ®Google Scholar
• Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014;35(11):716–724.
   PubMed Web of Science ®Google Scholar
• Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT, et al. Pulmonary hypertension and congenital heart disease: an insight from the REHAP national registry. Int J Cardiol. 2015;184:717–723.
   PubMed Web of Science ®Google Scholar
• Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects results of treatment of patients with ventricular septal defects. Circulation. 1993;87(2 Suppl):I38–51.
   PubMed Web of Science ®Google Scholar
• Collins-Nakai RL, Rabinovitch M. Pulmonary vascular obstructive disease. Cardiol Clinic. 1993;11(4):675–687.
   PubMedGoogle Scholar
• Chi TL, Krovetz LJ. The pulmonary vascular bed in children with down syndrome. J Pediatr. 1975;86(4):533–538.
   PubMed Web of Science ®Google Scholar
• Van Albada ME, Berger RMF. Pulmonary arterial hypertension in congenital cardiac disease – the need for refinement of the evian-venice classification. Cardiol Young. 2008;18(01):10–17.
   PubMedGoogle Scholar
• Beghetti M, Galiè N. Eisenmenger syndrome. J Am Coll Cardiol. 2009;53(9):733–740.
   PubMed Web of Science ®Google Scholar
• Therrien J, Rambihar S, Newman B, et al. Eisenmenger syndrome and atrial septal defect: nature or nurture? Can J Cardiol. 2006;22(13):1133–1136.
   PubMed Web of Science ®Google Scholar
• Abou Hassan OK, Haidar W, Nemer G, et al. Clinical and genetic characteristics of pulmonary arterial hypertension in Lebanon. BMC Med Genet. 2018;19(1):89.
   PubMedGoogle Scholar
• Tatebe S, Sugimura K, Aoki T, et al. The efficacy of a genetic analysis of the BMPR2 gene in a patient with severe pulmonary arterial hypertension and an atrial septal defect treated with bilateral lung transplantation. Intern Med. 2017;56(23):3193–3197.
   PubMed Web of Science ®Google Scholar
• Zhu N, Welch CL, Wang J, et al. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Med. 2018;10(1):56.
   PubMedGoogle Scholar
• Drakopoulou M, Nashat H, Kempny A, et al. Arrhythmias in adult patients with congenital heart disease and pulmonary arterial hypertension. Heart. 2018;104(23):1963–1969.
   PubMed Web of Science ®Google Scholar
• Broberg CS, Jayaweera AR, Diller GP, et al. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. J Am Coll Cardiol. 2011;107:595–599.
   Google Scholar
• Dimopoulos K, Condliffe R, Tulloh RMR, et al. Echocardiographic screening for pulmonary hypertension in congenital heart disease. J Am Coll Cardiol. 2018;72(22):2778–2788.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery J-L, et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;2016(37):67–119.
   Google Scholar
• Moceri P, Dimopoulos K, Liodakis E, et al. Echocardiographic predictors of outcome in Eisenmenger syndrome. Circulation. 2012;126(12):1461–1468.
   PubMed Web of Science ®Google Scholar
• Post M, Janssens S, Vandewerf F, et al. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004;25(18):1651–1656.
   PubMed Web of Science ®Google Scholar
• D’Alto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy. Heart. 2010;96(18):1475–1479.
   PubMed Web of Science ®Google Scholar
• Kempny A, Dimopoulos K, Fraisse A, et al. Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension. J Am Coll Cardiol. 2019;73(20):2640–2642.
   PubMed Web of Science ®Google Scholar
• Adatia I, Kothari SS, Feinstein JA. Pulmonary hypertension associated with congenital heart disease. Chest. 2010;137(6):52S–61S.
   PubMed Web of Science ®Google Scholar
• Frescura C, Thiene G, Gagliardi M, et al. Is lung biopsy useful for surgical decision making in congenital heart disease? Eur J Cardiothorac Surg. 1991;5(3):118–123.
   PubMed Web of Science ®Google Scholar
• Wacker J, Shunts: BM. When to close them and when to create them for palliation. Adv Pulm Hypertens. 2020;19(1):16–20.
   Google Scholar
• Dimopoulos K, Diller GP,editors. Pulmonary Hypertension in Adult Congenital Heart Disease. Cham: Springer International Publishing. 2017. Available from: http://link.springer.com/https://doi.org/10.1007/978-3-319-46028-4
   Google Scholar
• Moller JH, Patton C, Varco RL, et al. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol. 1991;68(15):1491–1497.
   PubMed Web of Science ®Google Scholar
• Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease–long-term follow-up and prediction of outcome after surgical correction. Circulation. 1987;76(5):1037–1042.
   PubMed Web of Science ®Google Scholar
• Stout Karen K, Daniels Curt J, Aboulhosn Jamil A, et al. AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2018;2019(139):e698–e800.
   Google Scholar
• Baumgartner H, De Backer J, Babu-Narayan SV, et al. ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020:ehaa554.
   PubMedGoogle Scholar
• Dimopoulos K, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Adv Pulm Hypertens. 2007;6(3):126–135.
   Google Scholar
• Van Der Feen DE, Bartelds B, De Boer RA, et al., Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. Heart. 2019;105(4):276–282.
   PubMed Web of Science ®Google Scholar
• Dalvi B, Jain S, Pinto R. Device closure of atrial septal defect with severe pulmonary hypertension in adults: patient selection with early and intermediate term results. Catheter Cardiovasc Interv. 2019;93(2):309–315.
   PubMed Web of Science ®Google Scholar
• Sridhar A, Subramanyan R, Lakshmi N, et al. Do preoperative haemodynamic data and reactivity test predict the postoperative reversibility of pulmonary arterial hypertension in patients with large ventricular septal defect and borderline operability? Heart Asia. 2013;5(1):182–187.
   PubMedGoogle Scholar
• Balzer DT, Kort HW, Day RW, et al, Balzer DT, Kort HW, Day RW. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP test study group. Circulation. 2002;106(12 Suppl 1):I76–81.
   PubMedGoogle Scholar
• Beghetti M, Galiè N, Can BD. “Inoperable” congenital heart defects become operable in patients with pulmonary arterial hypertension? dream or reality?: operability of patients with PAH-CHD. Congenit Heart Dis. 2012;7(1):3–11.
   PubMed Web of Science ®Google Scholar
• Lopes AA, O’Leary PW. Measurement, interpretation and use of hemodynamic parameters. Cardiol Young. 2009;19(S1):8–12.
   PubMedGoogle Scholar
• Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a critical review. Pulm Circ. 2020;10(2):204589402091788.
   Web of Science ®Google Scholar
• Kijima Y, Akagi T, Takaya Y, et al. Treat and repair strategy in patients with atrial septal defect and significant pulmonary arterial hypertension. Circ J. 2016;80(1):227–234.
   PubMed Web of Science ®Google Scholar
• Bradley EA, Ammash N, Martinez SC, et al. “Treat-to-close”: non-repairable ASD-PAH in the adult. Int J Cardiol. 2019;291:127–133.
   PubMed Web of Science ®Google Scholar
• Constantine A, Dimopoulos K. Evaluating a strategy of PAH therapy pre-treatment in patients with atrial septal defects and pulmonary arterial hypertension to permit safe repair (“treat-and-repair”). Int J Cardiol. 2019;291:142–144.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhu X, Lv B, et al. Trial occlusion to assess the risk of persistent pulmonary arterial hypertension after closure of a large patent ductus arteriosus in adolescents and adults with elevated pulmonary artery pressure. Circ Cardiovasc Interv. 2014;7(4):473–481.
   PubMed Web of Science ®Google Scholar
• Sanchez-Recalde A, Oliver JM, Galeote G, et al. Atrial septal defect with severe pulmonary hypertension in elderly patients: usefulness of transient balloon occlusion. Rev Esp Cardiol. 2010;63(7):860–864.
   PubMed Web of Science ®Google Scholar
• Kempny A, Hjortshøj CS, Gu H, et al. Predictors of death in contemporary adult patients with Eisenmenger syndrome: a multicenter study. Circulation. 2017;135(15):1432–1440.
   PubMed Web of Science ®Google Scholar
• Diller GP, Kempny A, Inuzuka R, et al. Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart. 2014;100(17):1366–1372.
   PubMed Web of Science ®Google Scholar
• Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015;132(22):2118–2125.
   PubMed Web of Science ®Google Scholar
• Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115(8):1039–1050.
   PubMed Web of Science ®Google Scholar
• Moceri P, Kempny A, Liodakis E, et al. Physiological differences between various types of Eisenmenger syndrome and relation to outcome. Int J Cardiol. 2015;179:455–460.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Ivy DD, Foreman AJ, et al. Four- and seven-year outcomes of patients with congenital heart disease–associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol. 2014;113(1):147–155.
   PubMed Web of Science ®Google Scholar
• Kuo S, Tandon R, Boggio L. Refractory severe thrombocytopenia associated with intravenous treprostinil use: a case report. Blood. 2008;112(11):4566.
   Google Scholar
• Martínez-Lavín M, Matucci-Cerinic M, Jajic I, et al. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol. 1993;20(8):1386–1387.
   PubMed Web of Science ®Google Scholar
• Silveira LH, Martínez-Lavín M, Pineda C, et al. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol. 2000;91(1):57–62.
   Google Scholar
• Garske LA, Bell SC. Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest. 2002;121(4):1363–1364.
   PubMed Web of Science ®Google Scholar
• Angel-Moreno Maroto A, Martínez-Quintana E, Suárez-Castellano L, et al. Painful hypertrophic osteoarthropathy successfully treated with octreotide the pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology (Oxford). 2005;44(10):1326–1327.
   PubMed Web of Science ®Google Scholar
• Opotowsky AR, Moko LE, Ginns J, et al. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease. J Clin Endocrinol Metab. 2015;100(4):1325–1334.
   PubMed Web of Science ®Google Scholar
• Kempny A, Dimopoulos K, Alonso-Gonzalez R, et al. Six-minute walk test distance and resting oxygen saturations but not functional class predict outcome in adult patients with Eisenmenger syndrome. Int J Cardiol. 2013;168(5):4784–4789.
   PubMed Web of Science ®Google Scholar
• Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001;164(9):1682–1687.
   PubMed Web of Science ®Google Scholar
• Gonzaga LRA, Matos-Garcia BC, Rocco IS, et al. Effects of acute oxygen supplementation on functional capacity and heart rate recovery in Eisenmenger syndrome. Int J Cardiol. 2017;231:110–114.
   PubMed Web of Science ®Google Scholar
• Diller G-P, Dimopoulos K, Broberg CS, et al. et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J. 2006;27(14):1737–1742
   Google Scholar
• Ammash N. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996;28(3):768–772.
   PubMed Web of Science ®Google Scholar
• Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol. 2006;48(2):356–365.
   PubMed Web of Science ®Google Scholar
• Kaemmerer H, Fratz S, Braun SL, et al. Erythrocyte indexes, iron metabolism, and hyperhomocysteinemia in adults with cyanotic congenital cardiac disease. Am J Cardiol. 2004;94(6):825–828.
   PubMed Web of Science ®Google Scholar
• Van de Bruaene A, Delcroix M, Pasquet A, et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J. 2011;32(22):2790–2799.
   PubMed Web of Science ®Google Scholar
• Tay ELW, Peset A, Papaphylactou M, et al., Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011;151(3): 307–312.
   PubMed Web of Science ®Google Scholar
• Blanche C, Alonso-Gonzalez R, Uribarri A, et al. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension. Int J Cardiol. 2018;267:79–83.
   PubMed Web of Science ®Google Scholar
• Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol. 2003;42(11):1982–1987.
   PubMed Web of Science ®Google Scholar
• Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007;50(7):634–642.
   PubMed Web of Science ®Google Scholar
• Hjortshøj CS, Kempny A, Jensen AS, et al. Past and current cause-specific mortality in Eisenmenger syndrome. Eur Heart J. 2017;38(26):2060–2067.
   PubMed Web of Science ®Google Scholar
• Habib G, Lancellotti P, Antunes MJ, et al. ESC guidelines for the management of infective endocarditisthe task force for the management of infective endocarditis of the European Society of Cardiology (ESC)endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;(36): 3075–3128.
   PubMed Web of Science ®Google Scholar
• Baddour Larry M, Wilson Walter R, Bayer Arnold S, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435–1486.
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Diller GP, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2008;117(18):2320–2328.
   PubMed Web of Science ®Google Scholar
• Ammash NM, Connolly HM, Abel MD et al. Noncardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol. 1999;33(1):222–227.
   PubMed Web of Science ®Google Scholar
• Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010;31(17):2124–2132.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;2018(39):3165–3241.
   Google Scholar
• Presbitero P, Somerville J, Stone S, et al. Pregnancy in cyanotic congenital heart disease outcome of mother and fetus. Circulation. 1994;89(6):2673–2676.
   PubMed Web of Science ®Google Scholar
• Galiè N, Beghetti M, Gatzoulis MA, et al., Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.
   PubMed Web of Science ®Google Scholar
• Apostolopoulou SC, Manginas A, Cokkinos DV, et al. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart. 2005;91:1447–1452.
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98(1):147–151.
   PubMed Web of Science ®Google Scholar
• Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart. 2007;93(8):974–976.
   PubMed Web of Science ®Google Scholar
• D’Alto M, Vizza CD, Romeo E, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart. 2007;93(5):621–625.
   PubMed Web of Science ®Google Scholar
• van Loon RLE, Hoendermis ES, Duffels MGJ, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J . 2007;154(4):776–782.
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Beghetti M, Galiè N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127(1):27–32.
   PubMed Web of Science ®Google Scholar
• Duffels MGJ, Vis JC, van Loon RLE, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without down’s syndrome. Am J Cardiol. 2009;132(9):1309–1315.
   Google Scholar
• Duffels MGJ, Vis JC, van Loon  RLE, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134(3):378–383.
   PubMed Web of Science ®Google Scholar
• Jing ZC, Strange G, Zhu XY, et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2010;29(2):150–156.
   PubMedGoogle Scholar
• Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164(1):64–69.
   PubMed Web of Science ®Google Scholar
• Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012;32(5):379–384.
   Google Scholar
• Zuckerman WA, Leaderer D, Rowan CA, et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol. 2011;107(9):1381–1385.
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Landzberg M, Beghetti M, et al., Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomized, controlled MAESTRO study. Circulation. 2019;139(1): 51–63.
   PubMed Web of Science ®Google Scholar
• Chau EMC, Fan KYY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007;120(3):301–305.
   PubMed Web of Science ®Google Scholar
• Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol. 2007;120(3):306–313.
   PubMed Web of Science ®Google Scholar
• Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011;97(22):1876–1881.
   PubMed Web of Science ®Google Scholar
• Tay ELW, Papaphylactou M, Diller GP, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol. 2011;149(3):372–376.
   PubMed Web of Science ®Google Scholar
• Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151(4):851.e1–5.
   Web of Science ®Google Scholar
• Mukhopadhyay S, Nathani S, Yusuf J, et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome–a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis. 2011;89(5):424–431.
   Google Scholar
• Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91(5):632–635.
   PubMed Web of Science ®Google Scholar
• Nashat H, Harries C, Parfitt L, et al. A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome. European Respiratory Journal [Internet]. 2018 [cited 2020 Aug 12];52. Available from: https://erj.ersjournals.com/content/52/suppl_62/PA3046
   Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–804.
   PubMed Web of Science ®Google Scholar
• D’Alto M, Constantine A, Balint OH, et al. The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome. Eur Respir J. 2019;54(5):1901401.
   PubMed Web of Science ®Google Scholar
• Barnikel M, Kneidinger N, Klenner F, et al. Real-life data on selexipag for the treatment of pulmonary hypertension. Pulm Circ. 2019;9(1):204589401983219.
   Web of Science ®Google Scholar
• El-Kersh K, Suliman S, Smith JS. Selexipag in congenital heart disease–associated pulmonary arterial hypertension and eisenmenger syndrome: first report. Am J Ther. 2018;25(6):e714–e715.
   PubMed Web of Science ®Google Scholar
• Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31(15):1898–1907.
   PubMed Web of Science ®Google Scholar
• Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31(9):1124–1131.
   PubMed Web of Science ®Google Scholar
• Diller GP, Körten MA, Bauer UMM, et al. Current therapy and outcome of Eisenmenger syndrome: data of the German national register for congenital heart defects. Eur Heart J. 2016;37(18):1449–1455.
   PubMed Web of Science ®Google Scholar
• Hascoet S, Fournier E, Jaïs X, et al. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: a French multicentre study. Arch Cardiovasc Dis. 2017;164(5):303–316.
   Google Scholar
• Arnott C, Strange G, Bullock A, et al. Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. Heart. 2018;104(9):732–737.
   Web of Science ®Google Scholar
• Khoshbin E, Reinhardt Z, Kirk R, et al. (1032) - The outcome of cardiac transplantation in patients with down syndrome. J Heart Lung Transplant. 2018;37(4):S401.
   PubMedGoogle Scholar
• Hjortshøj CS, Gilljam T, Dellgren G, et al. Outcome after heart–lung or lung transplantation in patients with Eisenmenger syndrome. Heart. 2020;106(2):127–132.
   PubMed Web of Science ®Google Scholar
• Esch JJ, Shah PB, Cockrill BA, et al. Transcatheter potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant. 2013;32(4):381–387.
   PubMed Web of Science ®Google Scholar
• Eisenmenger V. Die angeborenen defecte der kammerscheidewand des herzens. Z Klin Med. 1987;32:1–28.
   Google Scholar